MedTrace Logo

Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer

NCT00283075 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2019-01-16

Study results available
· View outcomes & findings →

Summary

This is a phase 1 trial to evaluate the safety and toxicity of mouse kidney cancer cell-containing agarose-agarose macrobeads that are implanted in the abdominal cavity as a proposed biological treatment of patients with end-stage, treatment-resistant cancer. The macrobeads have been extensively tested in tumor models in mice and rats, as well as in forty-five veterinary patients (cats and dogs) with naturally occurring tumors of various types including breast cancer, prostate cancer, liver cancer, and lymphoma with clear tumor responses and no significant detectable toxicity.

Conditions

  • Intraabdominal Cancers (Various Types)

Interventions

BIOLOGICAL

Cancer Macrobead placement in abdominal cavity

8 macrobeads per kg

Sponsors & Collaborators

  • The Rogosin Institute

    lead OTHER

Principal Investigators

  • Barry H Smith, MD, PhD · The Rogosin Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2012-12-31
Completion
2015-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00283075 on ClinicalTrials.gov